|
“Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organization”
Zhang Y., Glass A., Bennett N., Oyama K.A., Gehan E., Gelmann E.P.
In this study the long-term outcome
of recurrence free and overall survival was reported
on 750 radical prostatectomy patients treated between
1970 and 1996. From the date of diagnosis, prostatectomy
patients experienced an overall survival rate of 15.7
years, which is closest to the expected survival of
16.2 years. Approximately 75% of prostatectomy outcomes
were progression free for 10.6 years or greater. Prostatectomy
patients reported a Gleason score less than or equal
to 6, stage T1 or stage T2 tumor status, and a younger age at diagnosis.
“Radical Prostatectomy in the Management of Clinically Localized Prostate Cancer”
Catalona W.J, Smith D.S.
Dr. Catalona and associates reported
on their series of 1, 778 radical prostatectomy patients.
There were 38 patients with stage T1 and 60 with stage
T2. Of the prostatectomy patients 78 experienced progression-free
survival during a 5 year period and 65 during a 10 year
period.
“Radical Prostatectomy in the Management of Clinically Localized Prostate Cancer”
Pound C.R., Partin A.W., Epstein J.I., et al.
Dr. Pound and associates reported on 1, 623 prostatectomy patients, of which 38 were in stage T1 and 60 in T2. Their findings were similar to those of Drs. Catalona and Smith. Of the 1, 623 radical prostatectomy patients, 80 experienced progression-free prostatectomy survival during a 5-year period and 68 during a 10-year period.
“Radical Prostatectomy in the Management of Clinically Localized Prostate Cancer”
Zincke H., Oesterling J.E., Blute M.L., et al.
Dr. Zincke and associates reported on a larger series consisting of 3,170 radical prostatectomy patients. There were just 7 patients with stage T1 and 93 with T2. Their results found 70 radical prostatectomy patients with a progression-free survival rate at 5 years and 52 in ten years.
“Treatment Options for Prostate Cancer: Evaluating the Evidence”
Holmberg L., Bill-Axelson A., Helgesen F., Salo J.O., Folmerz P., Haggman M., et al.
Physicians studied 695 radical prostatectomy patients with clinically localized prostate cancer. They focused on men 65 and over, following up their prostate removal after 6.2 years. The majority of prostatectomy patients had a Gleason score of 5 or 6. Only about 5% were diagnosed by a PSA (prostate specific antigen) test, while more than one third were diagnosed due to recognizable symptoms. After 8 years only 7% of patients developed metastases. Adjusting for age, Gleason score, and stage, the relative rate of death from prostate cancer remained at 0.45.
“Treatment Options for Prostate Cancer: Evaluating the Evidence”
Blute M.L., Bergstralh E.J., Iocca A., Scherer B., Zincke H.
Physicians kept track of 2, 518 patients with prostate cancer who chose radical prostatectomy as their treatment between 1990 and 1993. Generally doctors followed up with patients 5.6 years after their prostate removal. The majority of patients had a Gleason score of 5 to 6 and less than 20% were diagnosed as a result as a PSA test. At five years, 73% to 83% of prostatectomy patients were alive and free of disease.
“Treatment Options for Prostate Cancer: Evaluating the Evidence”
Han M., Partin A.W., Zahurak M., Piantadosi S., Epstein J.I., Walsh P.C.
Dr. Han and associates conducted a study of 2,091 patients who had undergone radical prostatectomy between 1982 and 1999. The greater part of these prostatectomy patients had a Gleason score of 5 to 6 and 40% were diagnosed from a PSA test. In this study the biochemical recurrence-free survival rate for 5 years following their surgery reached 84%, in 10 years 72%, and in 15 years 63%. The corresponding metastases-free survival rate was 96%, 89%, and 81%.
|
